[Featured Stock] Nivek Rises on Highlighted Discussions with Moderna on mRNA Vaccine Delivery Technology
[Asia Economy Reporter Minwoo Lee] Naivek's stock price is on the rise. It appears that the fact that it has discussed technology related to Moderna and mRNA vaccine delivery platforms has been highlighted.
As of 2:19 PM on the 17th, Naivek's stock price recorded 34,900 KRW, up 7.72% from the previous day. The news that it has discussed the vaccine delivery platform technology with Moderna, which is developing a COVID-19 vaccine using mRNA, seems to have been emphasized.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Contracts Signed Without Viewing at 1.6 Billion Won"... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- [Breaking] Blue House expresses "deep regret over Samsung negotiation breakdown... urges both sides to do their best for a final agreement"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Naivek is developing a drug delivery platform technology called NIPEP-TPP. This technology uses peptides, the minimal units of proteins, to accurately deliver drugs to the desired cells or tissues within the body. The peptide technology developed by Naivek has shown effectiveness up to the preclinical stage. Since it is expected to take considerable time until clinical completion, Naivek is seeking early technology transfer or joint development. In fact, at the JP Morgan Healthcare Conference held last January, it conducted technology-related discussions with Moderna, Johnson & Johnson, Daiichi Sankyo, Otsuka, Merck, and others.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
